Stocktoria
Vistagen Therapeutics, Inc. VTGN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-10-18
Vistagen Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $486,000 | $1.1M | -$227,000 | $1.1M |
| R&D expense | $55.0M | $39.4M | $20.0M | $44.4M | $35.4M |
| Operating income | -$72.1M | -$56.0M | -$33.0M | -$59.3M | -$47.8M |
| Income tax | $7,000 | $7,000 | $4,000 | $6,000 | $3,400 |
| Net income | -$69.7M | -$51.4M | -$29.4M | -$59.2M | -$47.8M |
| EPS (diluted) | $-1.83 | $-1.67 | $-1.52 | $-8.51 | — |
| Operating cash flow | -$66.4M | -$42.1M | -$25.8M | -$49.7M | -$45.3M |
| Free cash flow | — | — | — | — | -$45.5M |
| Cash & equivalents | $30.8M | $67.1M | $119.2M | $16.6M | $68.1M |
| Total assets | $48.6M | $84.3M | $123.7M | $21.1M | $74.6M |
| Total liabilities | $13.0M | $14.0M | $9.4M | $9.0M | $9.9M |
| Shareholders' equity | $35.5M | $70.4M | $114.3M | $12.1M | $64.7M |
Source: SEC EDGAR filings · CIK 0001411685 · as of 2026-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.